Our STN: BL 125755/91

SUPPLEMENT APPROVAL
August 7, 2025

bluebird bio, Inc.
Attention: Julie Batal, MBA, JD
455 Grand Union Boulevard
Somerville, MA 02145

Dear Julie Batal:

We have approved your request received April 30, 2025, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for elivaldogene autotemcel (SKYSONA) to include new safety information (NSI) regarding the risk of hematologic malignancy following administration of SKYSONA, in Boxed Warning; Section 1, Indications and Usage; Section 5, Warnings and Precautions; Section 6 Adverse Reactions (6.1 Clinical Trials Experience) of the Prescribing Information and the Medication Guide, in accordance with section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FDCA).

The review of this supplement was associated with our April 3, 2025, SAFETY LABELING CHANGE NOTIFICATION LETTER, notifying you, under Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FDCA), of new safety information that we believe should be included in the labeling for elivaldogene autotemcel. This information pertains to the increased risk of hematological malignancy as observed in clinical study participants who received elivaldogene autotemcel.

LABELING

Under 21 CFR 201.57(c)(18), patient labeling must be referenced in section 17 PATIENT COUNSELING INFORMATION. Patient labeling must be available and may either be reprinted immediately following the full prescribing information of the package insert or accompany the prescription product labeling.

We hereby approve the draft content of labeling including the Package Insert and Medication Guide submitted under amendment 3, dated July 28, 2025.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described

at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert and Medication Guide submitted on July 28, 2025. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as a Product Correspondence to this BLA, STN BL 125755 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Asha Das, MD
Acting Director
Division of General Medicine
Office of Clinical Evaluation
Office of Therapeutic Products
Center for Biologics Evaluation and Research